|
Market Cap (24-Jun) $26,913,880 (1,550th) |
Close (30-Jun) $0.070 |
Volume (30-Jun) 333,655 |
Shortsold (6-Jun) 304 (0.00%) (624th) |
|
52w High $0.155 |
52w Low $0.052 |
P/E - |
EPS -0.02 |
A news article has been posted about BCAL Diagnostics on the AFR. The article was published around , on 17 March 2022 at 5:33am.
Overseas CEOs from Chimeric Therapeutics, BCAL Diagnostics and Radiopharm Theranostics are fronting local investors, hoping to shore up support amid the sell-off.
Read ArticleBDX was $0.090 at the close of trade on 16 March 2022
| Recent Articles about ASX:BDX | |
|---|---|
| 20-Dec | BCAL Diagnostics Ltd (BDX)
uk.investing.com |
| 19-Dec | BCAL Diagnostics Issues Shares to Boost Growth
markets.businessinsider.com |
| 19-Dec | BCAL Diagnostics Issues New Performance Rights
markets.businessinsider.com |
| 19-Dec | BCAL Diagnostics to Issue 12 Million Unlisted Options
nasdaq.com |
| 12-Dec | BCAL Diagnostics Limited BDX.AX
securities.io |
| 22-Nov | BCAL Diagnostics Gains Strong Support in AGM Resolutions
nasdaq.com |
| 5-Nov | Health Check: Which biotech boards are at risk of a ‘second strike’?
msn.com |
| 4-Nov | BCAL Diagnostics Ltd (BDX)
investing.com |
| 2-Sep | BCAL Diagnostics Limited's (ASX:BDX) Profit Outlook
sg.finance.yahoo.com |
| 2-Sep | BCAL Diagnostics Limited's (ASX:BDX) Profit Outlook
finance.yahoo.com |
| Tracked |
Find all articles about BCAL Diagnostics, including others on the AFR, on the media page.
You must be logged in to post a reply.
